AnalytischDenker schreef op 14 februari 2018 07:35:
[...]
CSL Analyst Presentation
www.csl.com/-/media/documents/5/2018-... Pagina 3:
Exceptionally strong HAEGARDA launchPagina 7:
HAEGARDA
Very successful chronic drug launch in the US- Natural C1-INH replacing missing or dysfunctional protein
Verder maakt HAE-medicijnen maar een klein onderdeel uit van CSL Limited. Totaal Financieel:
www.csl.com/-/media/documents/5/2018-... Half jaar resultaten (gebroken boekjaar)::Revenue $4,147 million, up 11% at CC
Earnings before interest and tax (EBIT) $1,476 million, up 31% at CC
NPAT $1,086 million, up 31% at CC
EPS $2.40, up 32% at CC
Interim dividend3 increased to $0.79 per share, up 23%